UBS analyst Dan Leonard raised the firm’s price target on Guardant Health (GH) to $110 from $80 and keeps a Buy rating on the shares. With another beat and raise, UBS sees multiple catalysts ahead for Guardant Health, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $100 from $65 at Citi
- Guardant Health price target raised to $100 from $80 at BTIG
- Guardant Health price target raised to $100 from $75 at Mizuho
- Guardant Health price target raised to $85 from $70 at Barclays
- Guardant Health price target raised to $100 from $75 at Canaccord